Cyclacel Pharmaceuticals (NASDAQ:CYCC) Issues Quarterly Earnings Results

Cyclacel Pharmaceuticals (NASDAQ:CYCC) announced its earnings results on Wednesday. The biotechnology company reported ($0.33) earnings per share for the quarter, Zacks reports. Cyclacel Pharmaceuticals had a negative return on equity of 1,901.11% and a negative net margin of 18,150.00%.

Cyclacel Pharmaceuticals Trading Down 8.8 %

NASDAQ:CYCC traded down $0.02 during mid-day trading on Wednesday, hitting $0.25. The stock had a trading volume of 295,405 shares, compared to its average volume of 1,203,308. Cyclacel Pharmaceuticals has a twelve month low of $0.23 and a twelve month high of $4.00. The stock has a 50-day simple moving average of $0.33 and a two-hundred day simple moving average of $0.50. The company has a market capitalization of $1.54 million, a PE ratio of -0.03 and a beta of 0.28.

Insiders Place Their Bets

In other Cyclacel Pharmaceuticals news, CEO David E. Lazar sold 194,628,820 shares of the firm’s stock in a transaction on Wednesday, February 26th. The stock was sold at an average price of $0.03, for a total value of $5,838,864.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 23.97% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Separately, StockNews.com started coverage on Cyclacel Pharmaceuticals in a research report on Monday. They set a “sell” rating on the stock.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.